The best-documented associations in breast cancer show that adiponectin levels are reduced in cancer patients vs. controls [34-36], and low adiponectin levels correlate with more aggressive tumors and higher frequency of lymph node metastasis [10,37]. This evidence concerns the gene ADIPOQ and metastatic malignant neoplasm in the lymph nodes.